WENA fundamentals

Anew Medical, Inc. engages in the provision of new therapies to treat neurodegenerative diseases. It operates through the following segments: Generic Drugs, Gene Therapy, and Pharmaceutical Programs. The Generic Drugs segment consists of portfolio of drugs and biosimilar biologics selling hard-to-source, difficult to find generic drugs and off-patent biologic therapies, and proprietary and patented technology platforms that include a library of melanocortin receptor-binding molecules. The Gene Therapy segment focuses on the gene therapy approach to introduce a therapeutic protein called “Klotho” inside the body to treat neurodegenerative diseases and other diseases of aging. The Pharmaceutical Programs segment includes treatments using small drug molecules that bind to the melanocortin receptors on human cells and affect skin pigmentation and other initiatives. The company was founded on August 2, 2004 and is headquartered in Omaha, NE.